<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="of infectious conjunctivitis, accounting for up to 75% of all" exact="conjunctivitis" post="cases and affecting people of all ages and demographics."/>
 <result pre="it can cause systemic infections in the form of gastroenteritis," exact="respiratory disease," post="and dissemination in immunocompromised individuals. HAdV causes lytic infection"/>
 <result pre="well as latent infection of lymphoid and adenoid cells. Epidemic" exact="keratoconjunctivitis" post="(EKC) is the most severe ocular manifestation of HAdV"/>
 <result pre="and future trends in prophylactic and therapeutic modalities for adenoviral" exact="keratoconjunctivitis" post="will be discussed. Keywords human adenovirus adenoviral keratoconjunctivitis antivirals"/>
 <result pre="for adenoviral keratoconjunctivitis will be discussed. Keywords human adenovirus adenoviral" exact="keratoconjunctivitis" post="antivirals immunotherapy povidone-iodine viral dissemination fig-count: table-count: ref-count: page-count:"/>
 <result pre="to the ocular surface, accounting for up to 75% of" exact="conjunctivitis" post="cases.1 The most common presentation is pharyngoconjunctival fever (PCF),"/>
 <result pre="fever, pharyngitis, rhinitis, follicular conjunctivitis, and regional lymphoid hyperplasia.2 Epidemic" exact="keratoconjunctivitis" post="(EKC) is the most severe ocular form and is"/>
 <result pre="to invade the corneal epithelium, ranging in presentation from a" exact="keratitis" post="to persistent and recurrent subepithelial infiltrates (SEIs). HAdV is"/>
 <result pre="host’s immune system. It is distinguished from other types of" exact="conjunctivitis" post="in that it often involves the cornea, with potentially"/>
 <result pre="and future trends in prophylactic and therapeutic modalities for adenoviral" exact="keratoconjunctivitis" post="will be discussed. Virology HAdV belongs to the genus"/>
 <result pre="3, 7, and 21 of Group B can cause keratoconjunctivitis," exact="urinary tract infection," post="respiratory infection, and GIT infection. Group D HAdV can"/>
 <result pre="demonstrated that Group D HAdV can be associated with concurrent" exact="urethritis" post="and conjunctivitis.22–26 HAdV 19 and 37 specifically have been"/>
 <result pre="et al discussed eight cases of individuals presenting with concurrent" exact="conjunctivitis" post="and adenoviral urethritis.23 Avolio et al also presented a"/>
 <result pre="a case of two male patients with HAdV D37 associated" exact="urethritis" post="and conjunctivitis, in which one of the spouses contracted"/>
 <result pre="and conjunctivitis, in which one of the spouses contracted adenoviral" exact="conjunctivitis" post="via oculogenital contact. These cases highlight the importance of"/>
 <result pre="of exotoxins (such as α-hemolysin, phospholipase C, and lipase) and" exact="suppression" post="of bacterial enzymes (such as elastase and ß-glucuronidase).32 Host"/>
 <result pre="drop is instilled. Anecdotally, patients may report exasperation of their" exact="conjunctivitis" post="symptoms for 12–24 hrs after this procedure; however, the"/>
 <result pre="The most powerful tool in limiting the severity of adenoviral" exact="conjunctivitis" post="outbreaks includes reduction of viral shedding and limiting contamination"/>
 <result pre="of 1.25% PVI ophthalmic solution in the treatment of pediatric" exact="conjunctivitis" post="displayed efficacy in treatment of bacterial, chlamydial, and viral"/>
 <result pre="pH 4.2 for enhanced tolerability) for the treatment of adenoviral" exact="keratoconjunctivitis" post="found faster recovery from disease at two weeks, with"/>
 <result pre="cause upper and lower respiratory tract disease, hemorrhagic cystitis, and" exact="gastroenteritis" post="due to its propensity to infect mucosal epithelium.3,41,42 Respiratory"/>
 <result pre="immunocompetent individuals, but in rare cases, severe respiratory infection and" exact="pneumonia" post="may result in acute respiratory distress syndrome (ARDS). Additionally,"/>
 <result pre="rare cases, severe respiratory infection and pneumonia may result in" exact="acute respiratory distress syndrome" post="(ARDS). Additionally, in immunocompromised patients undergoing hematopoietic stem cell"/>
 <result pre="in the inhibition of the herpes family of viruses, specifically" exact="herpes simplex" post="types 1 and 2, varicella-zoster virus, cytomegalovirus, and Epstein-Barr."/>
 <result pre="early systemic administration of CDV in immunocompetent patients with HAdV" exact="pneumonia" post="was an effective treatment strategy.42 Due to the positive"/>
 <result pre="resistance poses a significant challenge to the management of adenoviral" exact="keratoconjunctivitis" post="in the clinical setting.53 Romanowski et al were able"/>
 <result pre="likely to constitute a significant challenge in management of adenoviral" exact="keratoconjunctivitis" post="in immunocompetent patients. Drug-resistant viruses usually pose a minimal"/>
 <result pre="major challenge to the use of CDV for treating adenoviral" exact="keratoconjunctivitis" post="is its propensity to lead to toxicity, which manifests"/>
 <result pre="such as decreased vision, photophobia, halos, and the development of" exact="irregular astigmatism." post="Due to their chronicity and visual impact, treatments including"/>
 <result pre="SEIs, though they often end up resolving without scarring or" exact="corneal neovascularization" post="formation.2,12,62 Research demonstrates that mild corticosteroid treatment administered topically"/>
 <result pre="treatment is the risk of complications of long-term use, including" exact="glaucoma" post="and cataract formation.64–69 Additionally, corticosteroid treatment of SEIs can"/>
 <result pre="the risk of complications of long-term use, including glaucoma and" exact="cataract" post="formation.64–69 Additionally, corticosteroid treatment of SEIs can result in"/>
 <result pre="use and exhibit anti-inflammatory effects without the substantial risk of" exact="glaucoma" post="and cataract effect seen with steroid use. These agents"/>
 <result pre="exhibit anti-inflammatory effects without the substantial risk of glaucoma and" exact="cataract" post="effect seen with steroid use. These agents work on"/>
 <result pre="allergic conjunctivitis, alkali burns, herpetic uveitis, ocular trauma, and pre/post-operative" exact="cataract" post="and refractive surgeries.73–76 Gordon et al were the first"/>
 <result pre="substantia propria of mucous membranes; both are common in adenoviral" exact="keratoconjunctivitis" post="and may hemorrhage upon removal.1 Histopathological studies indicate the"/>
 <result pre="Because pseudomembrane formation can present in severe cases of adenoviral" exact="keratoconjunctivitis" post="in the setting of an intense inflammatory response (Figure"/>
 <result pre="tempering the host’s own immune response.77 Ocular use in HAdV" exact="keratoconjunctivitis" post="should be considered when there is a need to"/>
 <result pre="other day, in treatment of SEIs secondary to adenoviral epidemic" exact="keratoconjunctivitis" post="in cases persisting for more than three months. Patients"/>
 <result pre="ulcerative keratitis, Thygeson superficial punctate keratitis, herpes stromal keratitis, dry" exact="eye disease," post="superior limbic keratoconjunctivitis, and many others.69,79-81 Asena et al"/>
 <result pre="Asena et al also evaluated treatment options for acute adenoviral" exact="keratoconjunctivitis" post="using either topical 1% prednisolone acetate in conjunction with"/>
 <result pre="has ophthalmic uses, mainly in the treatment of giant papillary" exact="conjunctivitis" post="and vernal keratoconjunctivitis. With regards to its effect on"/>
 <result pre="200 years. More recently, they have also shown efficacy in" exact="cancer" post="treatments, in that treated patients demonstrated a lesser chance"/>
 <result pre="steroids as an antiviral agent for short-term treatment of adenoviral" exact="keratoconjunctivitis" post="as well as a prophylactic for use in individuals"/>
 <result pre="adenoviral keratoconjunctivitis.97 Conclusion and Future Perspectives Though many consider adenoviral" exact="conjunctivitis" post="a disease of self-limitation, the economic burden on affected"/>
 <result pre="the known disinfectant.103 Future considerations in the management of adenoviral" exact="keratoconjunctivitis" post="should require consideration of antisepsis and mitigation of sequelae"/>
 <result pre="Side effects of long-term corticosteroid use (ie, elevated IOP and" exact="cataract" post="formation) Immunotherapy such as topical cyclosporine or tacrolimus Corticosteroids"/>
 <result pre="22.AvolioM, De RosaR, ModoloML, StanoP, CamporeseA. When should adenoviral non-gonococcal" exact="urethritis" post="be suspected? Two case reports. New Microbiol. 2014;37(1):109–112.24531179 23.LiddleOL,"/>
 <result pre="reports. New Microbiol. 2014;37(1):109–112.24531179 23.LiddleOL, SamuelMI, SudhanvaM, EllisJ, TaylorC. Adenovirus" exact="urethritis" post="and concurrent conjunctivitis: a case series and review of"/>
 <result pre="2015;91(2):87–90. doi:10.1136/sextrans-2014-05186825433050 24.SamaraweeraGR, GarciaK, DruceJ, et al. Characteristics of adenovirus" exact="urethritis" post="among heterosexual men and men who have sex with"/>
 <result pre="BaiY, YangH. Analysis on the treatment and prevention of epidemic" exact="conjunctivitis" post="in 108 cases. Pak J Pharm Sci. 2017;30(4(Suppl.)):1501–1503.29044005 28.BuehlerJW,"/>
 <result pre="El-amirAN, MaddisonT, et al. Identification and control of nosocomial adenovirus" exact="keratoconjunctivitis" post="in an ophthalmic department. Br J Ophthalmol. 2009;93(1):18–20. doi:10.1136/bjo.2007.13011218697812"/>
 <result pre="et al. A controlled trial of povidone-iodine to treat infectious" exact="conjunctivitis" post="in children. Am J Ophthalmol. 2002;134(5):681–688. doi:10.1016/S0002-9394(02)01701-412429243 41.PhamTT, BurchetteJLJr.,"/>
 <result pre="46.HuangJ, KadonosonoK, UchioE. Antiadenoviral effects of ganciclovir in types inducing" exact="keratoconjunctivitis" post="by quantitative polymerase chain reaction methods. Clin Ophthalmol. 2014;8:315–320."/>
 <result pre="65.HillenkampJ, ReinhardT, RossRS, et al. Topical treatment of acute adenoviral" exact="keratoconjunctivitis" post="with 0.2% cidofovir and 1% cyclosporine: a controlled clinical"/>
 <result pre="67.ReinhardT, GodehardtE, PfahlHG, SundmacherR. [Local cyclosporin A in nummuli after" exact="keratoconjunctivitis" post="epidemica. A pilot study]. Ophthalmologe. 2000;97(11):764–768. German. doi:10.1007/s003470070025.11130165 68.KilicA,"/>
 <result pre="74.KesselL, TendalB, JorgensenKJ, et al. Post-cataract prevention of inflammation and" exact="macular edema" post="by steroid and nonsteroidal anti-inflammatory eye drops: a systematic"/>
 <result pre="nonsteroidal anti-inflammatory drugs to steroid drops for control of post" exact="cataract" post="surgery inflammation. Oman J Ophthalmol. 2016;9(3):150–156. doi:10.4103/0974-620X.19226827843229 76.DunnJP. Uveitis."/>
 <result pre="2005;24(1):86–91. doi:10.1097/01.ico.0000127481.23714.b615604872 79.LiegnerJT, YeeRW, WildJH. Topical cyclosporine therapy for ulcerative" exact="keratitis" post="associated with rheumatoid arthritis. Am J Ophthalmol. 1990;109(5):610–612. doi:10.1016/S0002-9394(14)70704-42333932"/>
 <result pre="YeeRW, WildJH. Topical cyclosporine therapy for ulcerative keratitis associated with" exact="rheumatoid arthritis." post="Am J Ophthalmol. 1990;109(5):610–612. doi:10.1016/S0002-9394(14)70704-42333932 80.HollandEJ, OlsenTW, KetchamJM, et"/>
 <result pre="2009;26(8):776–783. doi:10.1007/s12325-009-0062-119756415 92.KovalyukN, KaisermanI, MimouniM, et al. Treatment of adenoviral" exact="keratoconjunctivitis" post="with a combination of povidone-iodine 1.0% and dexamethasone 0.1%"/>
 <result pre="doi:10.3109/02713683.2014.96441925310347 95.GonzalezG, YawataN, AokiK, KitaichiN. Challenges in management of epidemic" exact="keratoconjunctivitis" post="with emerging recombinant human adenoviruses. J Clin Virol. 2019;112:1–9."/>
 <result pre="2014;112:38–46. doi:10.1016/j.antiviral.2014.10.00525453340 106.GordonYJ, NaesensL, DeClercqE, MaudgalPC, VeckeneerM. Treatment of adenoviral" exact="conjunctivitis" post="with topical cidofovir. Cornea. 1996;15(5):546. doi:10.1097/00003226-199609000-000188862935 107.KinchingtonPR, RomanowskiEG, Jerold"/>
</results>
